N-acetyltransferase 2 (arylamine N-acetyltransferase), also known as NAT2, is an enzyme which in humans is encoded by the NAT2 gene. [5] This gene encodes a type of N-acetyltransferase. The NAT2 isozyme functions to both activate and deactivate arylamine and …

Mar 30, 2025 · NAT2 (N-Acetyltransferase 2) is a Protein Coding gene. Diseases associated with NAT2 include Acetylation, Slow and Tuberculosis. Among its related pathways are Metapathway biotransformation Phase I and II and Paracetamol ADME.

Feb 8, 2025 · NAT2 slow acetylator genotype plays an important role in determining the risk of developing prostate cancer in Japanese men and is also associated with more clinically advanced and pathologically aggressive disease. NAT2 polymorphisms are associated with lung cancer

Jan 8, 2020 · NAT2 is one of only 2 N-acetyltransferase genes in humans; the other, NAT1, shows little variation between individuals, whereas NAT2 is known to have over 23 variants. N-acetyltransferases are enzymes acting primarily in the liver to detoxify a large number of chemicals, including caffeine and several prescribed drugs.

For NAT2, the acetylator phenotype is described as either slow, intermediate, or rapid. [17] Beyond modifying enzymatic activity, epidemiological studies have found an association of NAT2 polymorphisms with various cancers, likely from varying environmental carcinogens .

NAT2. NAT2 is in the colon, liver and small intestine. The enzyme N-acetyltransferase 2 acts primarily in the liver to detox several chemicals, caffeine, toxins, and prescription drugs. Depending on all your other NAT2 SNPs you can determine/alter your …

Jan 4, 2025 · Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.

Arylamine N-acetyltransferases (NATs) are polymorphic drug-metabolizing enzymes, acetylating arylamine carcinogens and drugs including hydralazine and sulphonamides. The slow NAT phenotype increases susceptibility to hydralazine and …

Apr 6, 2023 · The NAT2 clinical entails require a detailed landscape of its striking diversity. This systematic review spans the genetic and acetylation patterns from 164 articles from October 1992 to October 2020. Descriptive studies and controls from observational studies expanded the NAT2 diversity landscape.

Arylamine N -acetyltransferase 2 (NAT2) is a phase II xenobiotic-metabolising enzyme with medical relevance, responsible for the biotransformation of several therapeutic drugs, environmental and diet compounds [1 – 5].